Page 27 - 87_01
P. 27
ANALES 2012;18(3):212-24.
RANF 9. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago
www.analesranf.com M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained
response rate to peginterferon plus ribavirin in chronic hepatitis C pa-
5. CONCLUSIONES tients. Gastroenterology. 2005;128(3):636-41.
10. Garcia-Monzon C, Lo Iacono O, Mayoral R, Gonzalez-Rodriguez A, Mi-
Tomados en conjunto, los resultados derivados de este es- quilena-Colina ME, Lozano-Rodriguez T, et al. Hepatic insulin resistance
tudio traslacional indican que el sofosbuvir mejora la respuesta a is associated with increased apoptosis and fibrogenesis in nonalcoholic
la insulina alterada por la infección del VHC. De hecho, este estudio steatohepatitis and chronic hepatitis C. Journal of hepatology.
es especialmente relevante ya que es el primero que revela los me- 2011;54(1):142-52.
canismos moleculares implicados en la sensibilización a la insulina 11. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al.
hepática inducida por el tratamiento con sofosbuvir, que implica la Hepatitis C virus down-regulates insulin receptor substrates 1 and 2
recuperación de los niveles de proteína IRS1 como evento clave de through up-regulation of suppressor of cytokine signaling 3. The Ame-
sus efectos. rican journal of pathology. 2004;165(5):1499-508.
Conflicto de intereses 12. Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, et
al. The hepatitis C virus core protein of genotypes 3a and 1b downre-
Los autores declaran que NO tienen conflicto de intereses gulates insulin receptor substrate 1 through genotype-specific mecha-
y agradecen el apoyo financiero de la subvención CP14/00181 del nisms. Hepatology. 2007;45(5):1164-71.
Instituto de Salud Carlos III con financiada con fondos FEDER. 13. Ahmed QL, Manzoor S, Tariq M, Khalid M, Ashraf W, Parvaiz F, et al.
6. REFERENCIAS Hepatitis C virus infection in vitro triggers endoplasmic reticulum stress
1. WHO. Guidelines for the screening, care and treatment of persons and downregulates insulin receptor substrates 1 and 2 through upre-
gulation of cytokine signaling suppressor 3. Acta virologica.
with chronic hepatitis C infection. Guidelines for the Care and Treat- 2014;58(3):238-44.
ment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. 14. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. He-
WHO Guidelines Approved by the Guidelines Review Committee. Ge- patitis C virus core protein upregulates serine phosphorylation of insulin
neva2018. receptor substrate-1 and impairs the downstream akt/protein kinase
2. Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe B signaling pathway for insulin resistance. Journal of virology.
EC, et al. Changes in the Prevalence of Hepatitis C Virus Infection, 2008;82(6):2606-12.
Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Pa- 15. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis
tients With Cirrhosis or Liver Failure on the Waitlist for Liver Trans- C virus inhibits interferon signaling through up-regulation of protein
plantation. Gastroenterology. 2017;152(5):1090-9 e1. phosphatase 2A. Gastroenterology. 2004;126(1):263-77.
3. Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and he- 16. Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, et al. New
patitis C virus infection: A contemporary review. World journal of gas- Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C
troenterology. 2017;23(9):1697-711. Virus Infection: A Systematic Review of Randomized Controlled Trials.
4. Gastaldi G, Goossens N, Clement S, Negro F. Current level of evidence Journal of clinical and experimental hepatology. 2019;9(4):522-38.
on causal association between hepatitis C virus and type 2 diabetes: 17. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents
A review. Journal of advanced research. 2017;8(2):149-59. for the treatment of chronic hepatitis C. Expert opinion on investiga-
5. Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis tional drugs. 2013;22(9):1107-21.
and metabolic derangement. Alimentary pharmacology & therapeu- 18. Umar M, Akhter TS. New Direct Acting Antiviral Agents for the Treatment
tics. 2020;51(2):216-30. of Hepatitis C: 2016 and Beyond. Journal of the College of Physicians
6. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of and Surgeons--Pakistan : JCPSP. 2016;26(10):843-50.
diabetes: a systematic review and meta-analysis. Journal of hepato- 19. Herbst DA, Jr., Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor,
logy. 2008;49(5):831-44. for the treatment of chronic hepatitis C virus infection. Expert opinion
7. Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Pol S, et al. on investigational drugs. 2013;22(4):527-36.
Insulin resistance impairs sustained virological response rate to pegy- 20. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHut-
lated interferon plus ribavirin in HIV-hepatitis C virus-coinfected pa- chison JG, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in
tients: HOMAVIC-ANRS HC02 Study. Antiviral therapy. treatment-naive patients with HCV genotype 1: a randomized, 28-day,
2009;14(6):839-45.
8. El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance im-
pairs response to anti viral therapy. World journal of gastroenterology.
El tratamiento con sofosbuvir mejora la resistencia a la 25
insulina inducida por el virus de la hepatitis C
Esther Rey, Patricia Marañón y Águeda González-Rodríguez
An. Real Acad. Farm. Vol. 87. Nº1 (2021) · pp. 15 - 26
